Endocrinology, Vol 135, 2558-2567, Copyright © 1994 by Endocrine Society

ARTICLES

Expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein messenger ribonucleic acid levels in tissues of hypophysectomized rats infused with IGF-I and growth hormone

MA Gosteli-Peter, KH Winterhalter, C Schmid, ER Froesch and J Zapf
Department of Internal Medicine, University Hospital Zurich, Switzerland.

The expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 (IGFBP-2), -3, -4, and -5 messages were studied in liver, kidney, spleen, thymus, heart, brain, skeletal muscle, testes, and epididymal (white) adipose tissue (WAT) from hypophysectomized rats infused with saline, recombinant human (rh) IGF- I, or rhGH and compared with tissue messenger RNA (mRNA) levels in age- matched normal rats. The IGF-I message was present in all of these tissues. It was most abundant in liver and WAT, but was barely detectable in kidney, brain, and thymus. GH dependence was most pronounced in liver, skeletal muscle, and WAT and less so in heart, testes, kidney, spleen, and thymus. The IGF-I message in brain was not influenced by hypophysectomy. IGF-I infusion induced a small increase in its own mRNA in skeletal muscle and WAT, whereas it decreased its own message in liver. IGFBPs were expressed in a tissue-specific manner; IGFBP-2 mRNA was most abundant in testes and hypophysectomized liver, IGFBP-3 mRNA was most abundant in spleen, kidney, WAT, and liver, IGFBP-4 mRNA was most abundant in liver, and IGFBP-5 mRNA was most abundant in kidney, WAT, and skeletal muscle. After hypophysectomy, significant decreases in IGFBP expression were observed in liver (except IGFBP-2), skeletal muscle, brain, WAT (except IGFBP- 4), and testes (except IGFBP-2), in contrast to heart, kidney, spleen, and thymus. GH infusion did not affect IGFBP-2 mRNA levels in liver (in contrast to IGF-I infusion) or brain. Like GH, IGF-I normalized IGFBP-3 mRNA levels in liver, but, in contrast to GH, had no effect on IGFBP-5 mRNA in WAT. It was considerably less effective than GH in raising IGFBP-5 mRNA levels in skeletal muscle. Thus, GH infusion can exert different effects on IGF-I and IGFBP expression than infused rhIGF-I. Differences may be due to direct actions of GH at the tissue level, including auto/paracrine effects of locally produced IGF-I.

This article has been cited by other articles:

				M. L. Adamo, X. Ma, C. L. Ackert-Bicknell, L. R. Donahue, W. G. Beamer, and C. J. Rosen Genetic Increase in Serum Insulin-Like Growth Factor-I (IGF-I) in C3H/HeJ Compared with C57BL/6J Mice Is Associated with Increased Transcription from the IGF-I Exon 2 Promoter Endocrinology, June 1, 2006; 147(6): 2944 - 2955. [Abstract] [Full Text] [PDF]

				C. H. Lang, B. J. Krawiec, D. Huber, J. M. McCoy, and R. A. Frost Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R963 - R972. [Abstract] [Full Text] [PDF]

				S Shaikh, F H Bloomfield, M K Bauer, H H Phua, R S Gilmour, and J E Harding Amniotic IGF-I supplementation of growth-restricted fetal sheep alters IGF-I and IGF receptor type 1 mRNA and protein levels in placental and fetal tissues J. Endocrinol., July 1, 2005; 186(1): 145 - 155. [Abstract] [Full Text] [PDF]

				C. R. Croutch, M. Lebofsky, K.-W. Schramm, P. F. Terranova, and K. K. Rozman 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and 1,2,3,4,7,8-Hexachlorodibenzo-p-Dioxin (HxCDD) Alter Body Weight by Decreasing Insulin-Like Growth Factor I (IGF-I) Signaling Toxicol. Sci., May 1, 2005; 85(1): 560 - 571. [Abstract] [Full Text] [PDF]

				J. Woelfle and P. Rotwein In vivo regulation of growth hormone-stimulated gene transcription by STAT5b Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E393 - E401. [Abstract] [Full Text] [PDF]

				M. Hameed, K. H. W. Lange, J. L. Andersen, P. Schjerling, M. Kjaer, S. D. R. Harridge, and G. Goldspink The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men J. Physiol., February 15, 2004; 555(1): 231 - 240. [Abstract] [Full Text] [PDF]

				C. H. Lang, T. C. Vary, and R. A. Frost Acute in Vivo Elevation of Insulin-Like Growth Factor (IGF) Binding Protein-1 Decreases Plasma Free IGF-I and Muscle Protein Synthesis Endocrinology, September 1, 2003; 144(9): 3922 - 3933. [Abstract] [Full Text] [PDF]

				J. Zapf, M. Gosteli-Peter, G. Weckbecker, E. B. Hunziker, and M. Reinecke The Somatostatin Analog Octreotide Inhibits GH-Stimulated, But Not IGF-I-Stimulated, Bone Growth in Hypophysectomized Rats Endocrinology, August 1, 2002; 143(8): 2944 - 2952. [Abstract] [Full Text] [PDF]

				R. A. Frost, G. J. Nystrom, and C. H. Lang Regulation of IGF-I mRNA and Signal Transducers and Activators of Transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 Myoblasts Endocrinology, February 1, 2002; 143(2): 492 - 503. [Abstract] [Full Text] [PDF]

				K. Prelle, M. Stojkovic, K. Boxhammer, J. Motlik, D. Ewald, G. J. Arnold, and E. Wolf Insulin-Like Growth Factor I (IGF-I) and Long R3IGF-I Differently Affect Development and Messenger Ribonucleic Acid Abundance for IGF-Binding Proteins and Type I IGF Receptors in in Vitro Produced Bovine Embryos Endocrinology, March 1, 2001; 142(3): 1309 - 1316. [Abstract] [Full Text] [PDF]

				M. E. Wilson Insulin-Like Growth Factor I (IGF-I) Replacement during Growth Hormone Receptor Antagonism Normalizes Serum IGF-Binding Protein-3 and Markers of Bone Formation in Ovariectomized Rhesus Monkeys J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1557 - 1562. [Abstract] [Full Text]

				D. Chrysis and L. E. Underwood Regulation of Components of the Ubiquitin System by Insulin-Like Growth Factor I and Growth Hormone in Skeletal Muscle of Rats Made Catabolic with Dexamethasone Endocrinology, December 1, 1999; 140(12): 5635 - 5641. [Abstract] [Full Text]

				M. E. Wilson Effects of Estradiol and Exogenous Insulin-Like Growth Factor I (IGF-I) on the IGF-I Axis during Growth Hormone Inhibition and Antagonism J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4013 - 4021. [Abstract] [Full Text]

				M. Y. Donath, G. Sütsch, X.-W. Yan, B. Piva, H.-P. Brunner, Y. Glatz, J. Zapf, F. Follath, E. R. Froesch, and W. Kiowski Acute Cardiovascular Effects of Insulin-Like Growth Factor I in Patients with Chronic Heart Failure J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3177 - 3183. [Abstract] [Full Text]

				G. R. Adams and S. A. McCue Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats J Appl Physiol, May 1, 1998; 84(5): 1716 - 1722. [Abstract] [Full Text] [PDF]

				J. Nakae, M. Kato, M. Murashita, N. Shinohara, T. Tajima, and K. Fujieda Long-Term Effect of Recombinant Human Insulin-Like Growth Factor I on Metabolic and Growth Control in a Patient with Leprechaunism J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 542 - 549. [Abstract] [Full Text]

				E. J. Grossman, R. E. Grindeland, R. R. Roy, R. J. Talmadge, J. Evans, and V. R. Edgerton Growth hormone, IGF-I, and exercise effects on non-weightbearing fast muscles of hypophysectomized rats J Appl Physiol, November 1, 1997; 83(5): 1522 - 1530. [Abstract] [Full Text] [PDF]

				R. Clark The Somatogenic Hormones and Insulin-Like Growth Factor-1: Stimulators of Lymphopoiesis and Immune Function Endocr. Rev., April 1, 1997; 18(2): 157 - 179. [Abstract] [Full Text]

				R. V. Bhat, T. M. Engber, Y. Zhu, M. S. Miller, and P. C. Contreras Identification of Insulin-Like Growth Factor Binding Protein-2 as a Biochemical Surrogate Marker for the in Vivo Effects of Recombinant Human Insulin-Like Growth Factor-1 in Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 522 - 530. [Abstract] [Full Text]

				R. L. Duerr, M. D. McKirnan, R. D. Gim, R. G. Clark, K. R. Chien, and J. Ross Jr Cardiovascular Effects of Insulin-Like Growth Factor-1 and Growth Hormone in Chronic Left Ventricular Failure in the Rat Circulation, June 15, 1996; 93(12): 2188 - 2196. [Abstract] [Full Text]